On April 15, 2026, the FDA signaled a major shift in how a set of nominated peptide-related substances would be handled in the compounding pipeline. In Dr. Ashley Froese's telling, the practical effect was that a group of compounds long treated as effectively banned moved out of the strictest bucket and into active review. Since 2023, that stricter posture had functioned like a compounding ban in practice. Doctors could talk around peptides. Patients could hunt for them. But licensed pharmacies were not supposed to make them.

What changed, at least in one important sense, is that the pathway reopened for formal review.

What did not change is just as important. These compounds were not waved straight into legal, routine pharmacy compounding. They were moved out of outright prohibition and into a messy middle ground, what Dr. Ashley Froese describes as regulatory limbo.

This Spark exists because those two statements sound similar in a headline, and they are absolutely not the same in practice.

Froese 这支视频最重要的地方，不是煽动情绪，而是"翻译监管语言"。她做的是把一套又乱又硬的 FDA 流程，翻成普通人听得懂的话：是的，发生了重大变化，但这绝不等于你现在立刻就能合法拿到这些多肽。

从她的讲法看，一批从 2023 年起几乎被踢出合法复方体系的多肽相关物质，如今重新回到了"积极审查"的流程里。这就是真的变了的那一面。

外面常见的误读是——"FDA 给多肽开绿灯了。"更准确的说法是：审查流程重新动了，但合法供给的路径还没走完。Froese 把这个中间地带叫做"监管真空"。

这两句话在新闻标题里听起来很像，在现实里完全不是一回事。这个 Spark 就是为了把它们分清楚。

Froese's core argument is simple: the 2023 crackdown did not make peptides disappear. It pushed them underground.

Once legitimate compounding pathways narrowed, people who still wanted compounds like BPC-157, TB-500, or MOTS-c did what markets do when demand survives regulation — they found other sellers. In this case, that usually meant companies labeling products as research chemicals, not intended for human use, while knowing perfectly well why customers were buying them.

That is why this FDA move matters even before legal pharmacy access returns. It increases the odds that peptide demand will eventually move back into a system with actual standards.

这支视频里最有力的观点，不是医疗层面的，而是市场层面的：当监管把一个市场压下去，却没有把需求消灭掉时，市场不会消失，只会变形。

从 2023 年开始，想要 BPC-157、TB-500、MOTS-c 这类东西的人并没有突然消失。医生还是会被问，玩家还是会去找，需求还是会继续存在。结果就是，需求被挤进了灰色地带——贴着"仅供科研，不得人用"的标签流通。

所以这次变化的重要性，不在于药房明天就恢复正常，而在于灰市的存在逻辑开始松动。只要合法路径重新看起来有可能，讨论焦点就会慢慢回到证据、标准和流程上。

Froese is careful here. Her point is not that every peptide itself is automatically dangerous. Her point is that an unregulated supply chain is dangerous.

Some imported batches sold into the peptide market reportedly showed poor purity. Some sellers were not testing often enough. Some may have been shipping material that was never held to pharmacy-grade sterility standards in the first place.

That is the regulatory logic behind compounding oversight. A licensed pharmacy has rules about:

• sterility
• batch testing
• documentation
• environmental controls
• consistency from lot to lot

A research-chemical seller may not.

Froese 很克制。她不是在喊"这些多肽本身一定有毒"，她真正担心的是：一条没人认真把关的供应链，却在服务一批已经会往自己身上用的人。

市面上流通的部分进口批次，纯度据说很糟糕。一些卖家批次检测做得不够频繁，还有些人发出去的货，本来就从未按药房级无菌标准生产过。

合规复方药房为什么要有那一套规矩？因为它们必须盯住几件事：

• 无菌环境
• 批次检测
• 文件记录
• 环境控制
• 批与批之间的一致性

灰市卖家——不一定有这些。

The biggest misconception Froese is trying to kill is the idea that the FDA just made these peptides immediately legal to compound.

It did not.

Her warning is blunt: if a pharmacy tells you this list change alone means it can start selling these compounds right now, that is a red flag.

The current reality is more procedural than exciting. Removal from Category 2 only means the formal ban status changed. It does not create an automatic green light for prescribers, pharmacists, or patients.

Froese 最想打掉的误解是：FDA 并没有让这些多肽"立刻可以合法配制"。

没有。就是没有。

她的话说得很直：如果哪家药房现在就拿这次政策更新当作"可以开卖"的理由——那不是好消息，那是危险信号。

眼下的现实更像一套乏味的流程：从 Category 2 里移出来，只是"那个禁字不见了"，不是"医生、药师、患者自动开绿灯"。

The next stage runs through the Pharmacy Compounding Advisory Committee, or PCAC, the body that evaluates whether substances should move onto the approved compounding pathway. Here is the roadmap viewers actually need to understand:

• 2023 — high-interest peptides move into the effective compounding-ban era
• April 15, 2026 — FDA signals a meaningful policy shift and reopens review
• Now — official public comment period is open on the docket
• Late July 2026 — expected first PCAC review wave
• Later — more committee review and rulemaking
• Only after that — possible lawful routine pharmacy compounding

下一个阶段走的是药房复方咨询委员会（PCAC）——这个机构负责评估一种物质要不要进入合法的复方配制通道。下面这条时间线，是观众真正该盯住的那一条：

• 2023 年——高关注度多肽进入"事实上接近被禁配"的时代
• 2026 年 4 月 15 日——FDA 发出重大转向信号，正式审查重新启动
• 现在——联邦 docket 处于公开征求意见阶段
• 2026 年 7 月下旬——预计第一波 PCAC 审查
• 之后——还要继续走审查、程序和规则制定
• 再之后——才谈得上比较清楚的合法复方路径

First review wave, expected late July 2026:

• BPC-157 — reviewed in the context of ulcerative colitis and gut healing. Any approved indication could reopen a pharmacy pathway.
• TB-500 — under review for wound healing.
• KPV — under review for wound healing and inflammatory conditions.
• MOTS-c — under review for obesity and osteoporosis.
• Semax — under review for cerebral ischemia, stroke, migraines, and trigeminal neuralgia.
• Epitalon — under review for insomnia.
• DSIP — under review for opioid withdrawal, chronic insomnia, and narcolepsy.

Second review wave, expected February 2027:

• Melanotan II
• Dihexa
• LL-37
• GHK-Cu, specifically for injectable use

第一波（预计 2026 年 7 月下旬）：

• BPC-157——视频里放在溃疡性结肠炎和肠道修复的语境里讨论。更深一层的含义：只要任何一个适应症获批，合法复方的大门就开了一条缝。
• TB-500——伤口愈合方向。
• KPV——伤口愈合与炎症相关。
• MOTS-c——肥胖与骨质疏松。
• Semax——脑缺血、中风、偏头痛、三叉神经痛。
• Epitalon——失眠。
• DSIP——阿片戒断、慢性失眠、嗜睡症。

第二波（预计 2027 年 2 月）：

• Melanotan II
• Dihexa
• LL-37
• GHK-Cu（特别是注射型）

Yes, this is a meaningful regulatory shift. Yes, it raises the odds that peptide access could return to a more legitimate, pharmacy-based system. But no, this does not mean the peptide ban is simply over.

The best short summary is this:

• the outright prohibition weakened
• the legal pathway reopened
• the gray-market logic was exposed
• the real decision-making now moves to hearings, comments, and rulemaking

是的，这是一次重要的监管转向。是的，它削弱了过去那种把多肽长期冻住的监管逻辑。是的，它重新启动了正式流程。但它绝不是"一夜解禁"。

最干净的一段话总结是：

• 明确的禁令被削弱了
• 合法路径重新打开了
• 灰市的存在逻辑被摆到了台面上
• 真正的决定，现在移到了听证会、公众意见和规则制定里